- Entheon Biomedical Corp. (ENBI) is launching the EBIQ-101 observational trial with Wavepaths LLC to study the therapeutic effects of ketamine
- Wavepaths is a company which uses generative music technology for psychedelic therapy
- The study will follow how the brain activity changed in response to receiving a dose while using music to help personalize the patient’s experience
- Data on the impact of genetic markers and response to ketamine will also be analyzed
- Entheon Biomedical Corp. (ENBI) is unchanged trading at $0.20 per share as of 9:38 a.m. EST
Entheon Biomedical Corp. (ENBI) is launching the EBIQ-101 observational trial with Wavepaths LLC to study the therapeutic effects of ketamine.
Wavepaths is a company that uses generative music technology for psychedelic therapy.
EBIQ-101 will observe the electrical impulse (EEG) pattern of participants being treated with intramuscular ketamine for treatment-resistant major depressive disorder. The data collected will provide an understanding of brain activity changes in response to ketamine.
Recruitment for EBIQ-101 has been completed and the first patient dose is scheduled to occur later this week.
Timothy Ko, CEO of Entheon, commented,
“Music has long been considered a crucial element of the psychedelic therapy experience, so partnering with Wavepaths on this study is a great opportunity to further determine and discover the effect of audio in therapeutic settings,”
Wavepaths’ technology uses music to fully personalize the experience which is adapted live to suit the patient’s needs as they evolve during a therapy session. Integrating neuroscience, machine learning, music theory, and experience design to optimize music experiences for therapeutic outcomes will be a part of the platform in the EBIQ-101 study.
Wavepaths will also be gathering scientific evidence about how changes in musical structure connect with EEG measures of the brain’s activity during ketamine administration.
The ‘Psychedelic Music Questionnaire’ developed by Wavepaths, will also be used in the study. It can help the company to optimize its music system to create desired brain changes in patients receiving ketamine treatment for depression.
Genetic markers across participants will be compared, while data on the impact of genetic markers and response to ketamine will also be analyzed.
Entheon Biomedical Corp. (ENBI) is unchanged trading at $0.20 per share as of 9:38 a.m. EST.
